Effect of Insulin-like Growth Factor II on Protecting Myoblast Cells Against Cisplatin-induced Apoptosis Through P70 S6 Kinase Pathway

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2002 Aug 23

PMID 12192598

Citations 16

Authors

Xiaolin Wan

Lee J Helman

Affiliations

Soon will be listed here.

Abstract

Insulin-like growth factor (IGF-II) is overexpressed in a variety of human tumors and has both mitogenic and antiapoptotic activity. Although the mechanisms of IGF-II-induced proliferation have been well studied, the mechanisms underlying its survival signaling have been less well characterized. In this report, we investigated the role of IGF-II on cisplatin-induced apoptosis. We found that IGF-II overexpression was associated with an increase in p70 ribosomal protein S6 kinase (p70 S6K). Cisplatin treatment of C2C12 mouse myoblasts led to cell death associated with an inhibition of p70 S6K activity. Endogenous or exogenous IGF-II addition to C2C12 cells caused protection to cisplatin-induced apoptosis. This protection was associated in both cases with an increase in p70 S6K basal activity as well as resistance to cisplatin-induced decreased activity. Blockade of p70 S6K activation by rapamycin abrogated the IGF-II-mediated protection of cells to cisplatin-induced apoptosis. Furthermore, treatment of IGF-II-overexpressing Rh30 and CTR rhabdomyosarcoma cells with rapamycin restored sensitivity to cisplatin-induced apoptosis. These data together suggest that IGF-II-associated protection to cisplatin-induced apoptosis is mediated through an activation of the p70 S6K pathway. Thus, inhibition of the p70 S6 pathway may enhance chemotherapy-induced apoptosis in the treatment of IGF-II-overexpressing tumors.

Citing Articles

Bayesian Modeling Identifies PLAG1 as a Key Regulator of Proliferation and Survival in Rhabdomyosarcoma Cells.

Zheng Y, Xu L, Hassan M, Zhou X, Zhou Q, Rakheja D Mol Cancer Res. 2019; 18(3):364-374.

PMID: 31757836 PMC: 7056573. DOI: 10.1158/1541-7786.MCR-19-0764.

Caspase activity and apoptotic signaling in proliferating C2C12 cells following cisplatin or A23187 exposure.

Bloemberg D, Quadrilatero J Data Brief. 2016; 7:1024-30.

PMID: 27104214 PMC: 4826590. DOI: 10.1016/j.dib.2016.03.032.

The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells.

Li C, Xin P, Xiao H, Zheng Y, Huang Y, Zhu X Cancer Cell Int. 2015; 15:65.

PMID: 26130968 PMC: 4486138. DOI: 10.1186/s12935-015-0213-1.

IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.

Wan X, Yeung C, Heske C, Mendoza A, Helman L Neoplasia. 2015; 17(4):358-66.

PMID: 25925378 PMC: 4415145. DOI: 10.1016/j.neo.2015.03.001.

Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Hassan B, Akcakanat A, Holder A, Meric-Bernstam F Surg Oncol Clin N Am. 2013; 22(4):641-64.

PMID: 24012393 PMC: 3811932. DOI: 10.1016/j.soc.2013.06.008.

References

Pullen N, Thomas G . The modular phosphorylation and activation of p70s6k. FEBS Lett. 1997; 410(1):78-82. DOI: 10.1016/s0014-5793(97)00323-2. View

Nielsen F . The molecular and cellular biology of insulin-like growth factor II. Prog Growth Factor Res. 1992; 4(3):257-90. DOI: 10.1016/0955-2235(92)90023-b. View

Minniti C, Luan D, OGrady C, Rosenfeld R, Oh Y, Helman L . Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ. 1995; 6(3):263-9. View

Zhang L, Kim M, Choi Y, Goemans B, Yeung C, Hu Z . Diminished G1 checkpoint after gamma-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression. J Biol Chem. 1999; 274(19):13118-26. DOI: 10.1074/jbc.274.19.13118. View

Toretsky J, Helman L . Involvement of IGF-II in human cancer. J Endocrinol. 1996; 149(3):367-72. DOI: 10.1677/joe.0.1490367. View

Helman L, CHATTEN J, Steinberg S, Evans A, Israel M . Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest. 1991; 87(2):648-57. PMC: 296355. DOI: 10.1172/JCI115042. View

Fan S, Chang J, Smith M, Duba D, Fornace Jr A, OConnor P . Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene. 1997; 14(18):2127-36. DOI: 10.1038/sj.onc.1201052. View

Ullrich A, Gray A, Tam A, Tsubokawa M, Collins C, Henzel W . Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5(10):2503-12. PMC: 1167146. DOI: 10.1002/j.1460-2075.1986.tb04528.x. View

Polunovsky V, Gingras A, Sonenberg N, Peterson M, Tan A, Rubins J . Translational control of the antiapoptotic function of Ras. J Biol Chem. 2000; 275(32):24776-80. DOI: 10.1074/jbc.M001938200. View

10.

Felix C, Kappel C, Mitsudomi T, Nau M, Tsokos M, Crouch G . Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992; 52(8):2243-7. View

11.

Tee A, Proud C . DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene. 2000; 19(26):3021-31. DOI: 10.1038/sj.onc.1203622. View

12.

Reeve A, Eccles M, Wilkins R, Bell G, Millow L . Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature. 1985; 317(6034):258-60. DOI: 10.1038/317258a0. View

13.

Zamble D, Lippard S . Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995; 20(10):435-9. DOI: 10.1016/s0968-0004(00)89095-7. View

14.

Thomas G, Hall M . TOR signalling and control of cell growth. Curr Opin Cell Biol. 1998; 9(6):782-7. DOI: 10.1016/s0955-0674(97)80078-6. View

15.

Collett-Solberg P, Cohen P . The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am. 1996; 25(3):591-614. DOI: 10.1016/s0889-8529(05)70342-x. View

16.

Alaoui-Jamali M, Paterson J, Al Moustafa A, Yen L . The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol. 1997; 75(4):315-25. View

17.

von Manteuffel S, Gingras A, Ming X, Sonenberg N, Thomas G . 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci U S A. 1996; 93(9):4076-80. PMC: 39489. DOI: 10.1073/pnas.93.9.4076. View

18.

Burger A, Double J, Newell D . Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer. 1997; 33(4):638-44. DOI: 10.1016/s0959-8049(96)00521-7. View

19.

Jefferies H, Fumagalli S, Dennis P, Reinhard C, Pearson R, Thomas G . Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997; 16(12):3693-704. PMC: 1169993. DOI: 10.1093/emboj/16.12.3693. View

20.

Loehrer P, Einhorn L . Drugs five years later. Cisplatin. Ann Intern Med. 1984; 100(5):704-13. DOI: 10.7326/0003-4819-100-5-704. View